This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Hector H. Garcia, MD
Lima, Peru

Robert H. Gilman, MD
Department of International Health The Johns Hopkins University School of Hygiene and Public Health 615 N Wolfe St Baltimore, MD 21205

Arch Neurol. 1995;52(10):941.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the section "Controversies in Neurology" of the January issue of the ARCHIVES, Kramer¹ and Del Brutto² do a commendable job of defending opposed positions about the role of antiparasitic therapy in the management of neurocysticercosis. We would like, however, to discuss the final statements of the section editor, Dr Hachinski,³ that placebo-controlled therapeutic trials for neurocysticercosis are not plausible for ethical reasons.

The actual knowledge of the evolution of untreated cysticercosis is scarce and based on anecdotal case reports.^4,5 Selection bias affects the validity of these reports: cases with more severe symptoms will be more likely to be chosen for study since patients with milder symptoms will be less likely to seek medical attention. "Historical" controls (patients who had computed tomographic studies performed before treatment) have also shown that lesions do not significantly increase in number or size.^6,7 These historical controls were selected from . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?